CHILDHOOD ASTHMA MANAGEMENT PROGRAM - CONTINUATION STUDY - PHASE 2 (CAMP CS/2)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项对参加儿童哮喘管理计划(CAMP)的儿童进行的为期4年的观察性随访研究。CAMP是一项多中心随机临床试验，旨在确定三种治疗方法(沙丁胺醇、沙丁胺醇加吸入类固醇、沙丁胺醇加吸入非类固醇)对5-13岁轻度至中度哮喘儿童的疗效。这项研究的假设是，在夏令营期间吸入皮质类固醇不会改善肺功能，但会降低呼吸道反应性，不会影响身高和骨密度，并会减少症状的持续、缓解和复发，从而需要药物治疗。此外，下呼吸道症状、过敏、血嗜酸粒细胞增多、呼吸道反应性和个人吸烟会降低肺功能。最后，某些基因变异将与哮喘引起的肺功能发育障碍有关。研究的三个具体目标包括：1)下呼吸道症状、过敏、血嗜酸粒细胞增多、呼吸道反应性和个人吸烟对青年肺功能和反应性的影响；2)肺功能和呼吸道反应性、过敏、嗜酸性粒细胞增多和个人吸烟对青年下呼吸道症状的影响；3)与正常受试者相比，cAMP受试者与低FEV1/FVC有关的因素。 这项研究将是第一个确定青壮年预后决定因素的儿童哮喘研究，也是第一个检验强力抗炎药强化治疗对预后影响的研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a 4-year observational follow-up study of children enrolled in the Childhood Asthma Management Program (CAMP). CAMP was a multicenter randomized clinical trial designed to determine the effects of three treatments (albuterol, albuterol plus inhaled steroids, albuterol with inhaled non steroids) in children age 5-13 years with mild to moderate asthma. The hypothesis of this study is that inhaled corticosteroids used during CAMP will not benefit lung function but will decrease airway responsiveness, will not affect height and bone density, and will reduce persistence, remission and relapse of symptoms with resultant need of medication. Furthermore, increase in lower respiratory symptoms, allergy, blood eosinophilia, airway responsiveness, and personal smoking will decrease lung function. Finally, certain genotypic variants will be associated with impairment of growth of lung function caused by asthma. Three Specific Aims will be examined including 1) the effects of lower respiratory symptoms, allergy, blood eosinophilia, airway responsiveness, and personal smoking on attained level of lung function and reactivity in young adulthood 2) effects of lung function and airway reactivity, allergy, eosinophilia and personal smoking on lower respiratory symptoms in young adulthood and 3) factors associated with low FEV1/FVC in CAMP subjects versus normal subjects. This study will be the first study of childhood asthma to define the determinants of outcomes in young adulthood and the first to examine the effects of intensive treatment with potent anti-inflammatory agents on outcomes.